Highlights NextCure, Inc.

Equities

NXTC

US65343E1082

Market Closed - Nasdaq Other stock markets 01:30:00 29/06/2024 am IST			5-day change	1st Jan Change
1.59 ^USD	-3.05%		-1.85%	+39.47%

18/06	NextCure, Inc. Announces Retirement of Han Myint as Chief Medical Officer, Effective July 1, 2024	CI
30/05	NextCure, Inc. Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

NextCure, Inc. Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024	31/05	CI
NextCure, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	03/05	CI
NextCure, Inc. and LigaChem Biosciences, Inc. Present Preclinical Data on B7-H4 Antibody Drug Conjugate At AACR 2024	08/04	CI
NextCure, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03	CI
NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders	19/01	CI
Nextcure, Inc. Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury	21/12	CI
Nextcure, Inc. Provides Year-End Clinical Pipeline Updates	14/12	CI
NextCure, Inc. Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AML	16/11	CI
NextCure, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	03/11	CI
NextCure, Inc. Announces Presentation of New Preclinical Data Demonstrate Treatment with NC605	17/23/17	CI
NextCure, Inc. Presents Preclinical Data on Nc181, A Novel Therapeutic Candidate Targeting Apoe4, for the Treatment of Alzheimer's Disease	27/23/27	CI
NextCure, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	04/23/04	CI
NextCure, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	05/23/05	CI
NextCure, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	03/23/03	CI
NextCure, LegoChem Biosciences to Collaborate on Development of Antibody Drug Conjugates	16/22/16	MT
NextCure, Inc. and LegoChem Biosciences Enter into Collaboration and Co-Development Agreement to Develop Antibody Drug Conjugates	16/22/16	CI
NextCure Presents Initial Data from Clinical Trial of NC762 and a Trial in Progress Poster for NC410 Combo at the 2022 Society for Immunotherapy of Cancer Annual Meeting	07/22/07	CI
Earnings Flash (NXTC) NEXTCURE Posts Q3 Loss $-0.68	04/22/04	MT
NextCure, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	04/22/04	CI
NextCure, Inc. Announces Initiation of Phase 1b/2 Clinical Trial to Evaluate NC410 in Combination with KEYTRUDA (Pembrolizumab) in Patients with Immune Checkpoint Refractory or Naïve Solid Tumors	05/22/05	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights NextCure, Inc.

Equities

NXTC

US65343E1082

Highlights

Filters